The Australian share market is home to a wide range of biotech shares with significant potential.
While it is more risky than the average industry, I do think there are some quality options in it that could prove to be very rewarding investments in the long-term.
Three worth taking a closer look at are listed below:
CSL Limited (ASX: CSL)
The biotech giant is arguably one of the highest quality companies in Australia and deserving of a spot in almost all portfolios. Its shares may trade at quite a premium to the market average, but I believe the strong growth of its core business and fledgling influenza business go a long way to justifying this.
Cynata Therapeutics Ltd (ASX: CYP)
Through its impressive Cymerus technology, Cynata is able to produce an unlimited number of high quality and consistent stem cells at a low cost. These stem cells can then be used to treat a number of diseases including Graft versus Host Disease (GvHD), which the company is currently running a clinical trial for. The market opportunity for this treatment alone is estimated to be US$300 million a year.
Telix Pharmaceuticals Ltd (ASX: TLX)
This promising biotech is focused on research into targeted radiation solutions for treating cancer. Its CEO, Dr Christian Behrenbruch, is very respected in the industry and has a solid track record of success in the field. A broker note out of Wilsons recently revealed that it has placed a buy rating and 90 cents price target on its shares.
